| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ba2c4156354c844d4a8883be561f00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-6555 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-775 |
| filingDate |
2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d86cb60213087c44885c8bb0ceb8fa52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12edc32ee5c3b6124feb8d937456230f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97f33154c5d67135db9fe6a6d824a1e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e02f736c1f1e9e6ccdfc758cabb4b9 |
| publicationDate |
2016-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-342020-B |
| titleOfInvention |
APOLIPOPROTEIN A-IV AS AN ANTIDIABETIC PEPTIDE. |
| abstract |
The present invention relates to methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus; the methods include administering an effective amount of apolipoprotein A-IV to the subject; The pharmaceutical composition includes apolipoprotein A-1 formulated for administration to a subject for the treatment of type two diabetes mellitus; Methods are also described to substantially restore glucose tolerance in a subject in need thereof at a normal level and methods to decrease blood glucose concentrations in a subject in need thereof. |
| priorityDate |
2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |